Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 39

  • 872 clinical trials
  • 359 recruiting
  • 331 conditions
  • 28 countries

Conditions in this area

331 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis63Systemic lupus erythematosus63Psoriatic arthropathy46Myasthenia gravis44Systemic scleroderma40Sjogren's syndrome31Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis16Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+307

Clinical trials in Musculoskeletal and connective tissue disorders

872 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

872 clinical trials

Myasthenia gravis

Not yet recruiting

Study on the Safety and Effects of YTB323 and Drug Combination for Patients with Treatment-Resistant Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Muscular dystrophy

Not yet recruiting

Study on the Effectiveness of Deflazacort in Treating LMNA-related Congenital Muscular Dystrophy in Adults and Children

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Deflazacort
  • Sponsor:Azienda Ospedaliero Universitaria Pisana

Systemic lupus erythematosus

Not yet recruiting

Study on the Effectiveness of Telitacicept for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Remegen Co. Ltd.

Soft tissue sarcoma

Not yet recruiting

Study of Selinexor and Gemcitabine for Patients with Advanced Soft-Tissue Sarcoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas

Ewing's sarcoma

Not yet recruiting

Study on Treosulfan and Melphalan for High-Risk Ewing Sarcoma Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Santobono Pausilipon Onlus

Still's disease+1

Not yet recruiting

Study on Anakinra for Children with Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Anakinra
  • Sponsor:Universitair Medisch Centrum Utrecht

Soft tissue sarcoma

Not yet recruiting

Study of Selinexor and Gemcitabine for Patients with Advanced Soft-Tissue Sarcoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas

Desmoid tumour+2

Not yet recruiting

Study of Propranolol and Vinorelbine for Children and Teenagers with Refractory or Relapsing Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Vinorelbine Tartrate
  • Sponsor:Centre Hospitalier Regional De Marseille

Duchenne muscular dystrophy+1

Not yet recruiting

Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Delandistrogene Moxeparvovec
  • Sponsor:Sarepta Therapeutics Inc.

Leiomyosarcoma+5

Not yet recruiting

Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Intensity Therapeutics Inc.

Osteosarcoma metastatic

Not yet recruiting

Study on the Safety and Tumor-Fighting Effects of OMO-103 for Patients with Advanced Osteosarcoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:OMO-103
  • Sponsor:Vall D Hebron Institute Of Oncology

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate26 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.